EPHA2 is involved in numerous cellular processes and has been implicated in the progression of various cancers. It is known to influence cell morphology and motility by interacting with its ephrin ligands, which are membrane-bound proteins. The binding of ephrin ligands to EPHA2 triggers bidirectional signaling, affecting both the receptor-expressing and ligand-expressing cells.
The PAT66G9AT is a mouse monoclonal antibody specifically designed to target the human EPHA2 receptor. This antibody is produced by hybridizing mouse F0 myeloma cells with spleen cells from BALB/c mice that have been immunized with human EPHA2 . The resulting hybridoma cells produce the PAT66G9AT antibody, which can be used in various applications such as Western Blotting (WB), Immunocytochemistry (ICC), and Immunofluorescence (IF) .
The PAT66G9AT antibody is widely used in research to study the expression and function of EPHA2 in different cell types and tissues. It is particularly valuable in cancer research, where EPHA2 is often overexpressed and associated with tumor progression and metastasis. By using this antibody, researchers can investigate the role of EPHA2 in cancer and potentially develop targeted therapies.